Cargando…

Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review

Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to bette...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez-Pombo, Antia, Diaz-Lopez, Everardo Josue, Castro, Ana I., Sanchez-Iglesias, Sofia, Cobelo-Gomez, Silvia, Prado-Moraña, Teresa, Araujo-Vilar, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000975/
https://www.ncbi.nlm.nih.gov/pubmed/36899861
http://dx.doi.org/10.3390/cells12050725
_version_ 1784904017240915968
author Fernandez-Pombo, Antia
Diaz-Lopez, Everardo Josue
Castro, Ana I.
Sanchez-Iglesias, Sofia
Cobelo-Gomez, Silvia
Prado-Moraña, Teresa
Araujo-Vilar, David
author_facet Fernandez-Pombo, Antia
Diaz-Lopez, Everardo Josue
Castro, Ana I.
Sanchez-Iglesias, Sofia
Cobelo-Gomez, Silvia
Prado-Moraña, Teresa
Araujo-Vilar, David
author_sort Fernandez-Pombo, Antia
collection PubMed
description Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field.
format Online
Article
Text
id pubmed-10000975
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100009752023-03-11 Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review Fernandez-Pombo, Antia Diaz-Lopez, Everardo Josue Castro, Ana I. Sanchez-Iglesias, Sofia Cobelo-Gomez, Silvia Prado-Moraña, Teresa Araujo-Vilar, David Cells Systematic Review Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field. MDPI 2023-02-24 /pmc/articles/PMC10000975/ /pubmed/36899861 http://dx.doi.org/10.3390/cells12050725 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Fernandez-Pombo, Antia
Diaz-Lopez, Everardo Josue
Castro, Ana I.
Sanchez-Iglesias, Sofia
Cobelo-Gomez, Silvia
Prado-Moraña, Teresa
Araujo-Vilar, David
Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title_full Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title_fullStr Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title_full_unstemmed Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title_short Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
title_sort clinical spectrum of lmna-associated type 2 familial partial lipodystrophy: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000975/
https://www.ncbi.nlm.nih.gov/pubmed/36899861
http://dx.doi.org/10.3390/cells12050725
work_keys_str_mv AT fernandezpomboantia clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT diazlopezeverardojosue clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT castroanai clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT sancheziglesiassofia clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT cobelogomezsilvia clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT pradomoranateresa clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview
AT araujovilardavid clinicalspectrumoflmnaassociatedtype2familialpartiallipodystrophyasystematicreview